Skip to main content
Selvita S.A. logo

Selvita S.A. — Investor Relations & Filings

Ticker · SLV ISIN · PLSLVCR00029 LEI · 25940057WQ9YP5MOQF28 WAR Professional, scientific and technical activities
Open in API
Filings indexed 1,179 across all filing types
Latest filing 2019-03-28 Capital/Financing Update
Country PL Poland
Listing WAR SLV

About Selvita S.A.

https://selvita.com/

Selvita S.A. is a preclinical contract research organization (CRO) providing integrated services for the pharmaceutical and biotechnology sectors. The company offers comprehensive solutions across the drug discovery and development continuum, from target validation to preclinical candidate nomination. Core drug discovery capabilities include medicinal chemistry, pharmacology, DMPK, and protein sciences, supporting a wide range of modalities such as small molecules, antibodies, and protein degraders. For drug development, Selvita provides analytical support for small and large molecules, formulation, microbiology services, and manufacturing for clinical trials. The company operates under GMP and GLP quality standards, offering flexible engagement models that range from standalone studies to fully integrated programs.

Recent filings

Filing Released Lang Actions
Zawarcie znaczącej umowy dotacji z NCBiR - Content (PL)
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from the Management Board (Zarząd) of Selvita S.A. regarding the signing of a significant agreement (Umowa) with the National Centre for Research and Development (Narodowe Centrum Badań i Rozwoju) for project funding related to cancer therapy development. It details the total project value, the amount of funding received (dofinansowanie), and the project timeline. This announcement concerns a major financing/grant activity that impacts the company's capital structure and future operations, specifically related to R&D funding. This aligns best with the 'Capital/Financing Update' category (CAP), as it details a substantial grant/funding agreement, even though it is R&D focused, it represents a significant capital inflow/support structure. It is not a standard earnings release (ER), interim report (IR), or a general regulatory filing (RNS) given its specific financial/funding nature.
2019-03-28 Polish
Uzgodnienie i przyjęcie planu podziału Emitenta - Content (PL)
M&A Activity Classification · 99% confidence The document discusses a 'plan podziału' (division plan) involving the separation of a part of the company's assets (a segment of business operations) into a newly formed entity ('Spółka Przejmująca') through a spin-off mechanism ('podział przez wydzielenie'). It details the capital increase, the issuance of new shares ('Akcje Podziałowe') to existing shareholders in exchange for the transferred assets, and the subsequent steps for listing these new shares on the Warsaw Stock Exchange (GPW). This transaction fundamentally alters the company's capital structure and involves a significant corporate reorganization/financing event. This aligns best with the 'Capital/Financing Update' category, as it details the mechanics of issuing new shares as part of a corporate restructuring (spin-off). It is not a standard 10-K, AR, or IR. It is a specific announcement about a capital change resulting from a corporate action, making 'CAP' the most appropriate classification over general 'RNS' or 'LTR'.
2019-03-28 Polish
Przekazanie do publicznej wiadomości opóźnionej informacji poufnej - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document text is written in Polish and explicitly references Article 17 of Regulation (EU) No 596/2014 (MAR - Market Abuse Regulation) regarding the delayed disclosure of inside information. It states that the Management Board is now disclosing information that was previously delayed on February 14, 2019. The content of the disclosed information concerns a directional resolution regarding the division (spin-off) of the company (Selvita S.A.) through the transfer of a part of its assets (service segment) to another company, citing Article 529 § 1 point 4 of the Commercial Companies Code. This type of announcement, dealing with significant corporate restructuring (spin-off/division) and mandated by MAR disclosure rules, is a form of regulatory disclosure. Since it is not a standard Annual Report (10-K), Earnings Release (ER), or a specific financing event (CAP), it falls best under the general category for regulatory announcements or specific corporate actions. Given the context of a major structural change being announced under MAR, it is a significant regulatory filing. While 'TAR' (M&A Activity) might seem close, a spin-off is distinct from a takeover bid. 'RPA' is for announcing the publication of *other* reports. 'RNS' (Regulatory Filings) is the most appropriate general category for mandatory disclosures under EU regulations that don't fit a more specific code, especially when dealing with inside information disclosure procedures.
2019-03-28 Polish
Pismo Prezesa Zarządu
Management Reports Classification · 99% confidence The document is a formal address to shareholders ("Drodzy Akcjonariusze Selvity!") from the CEO ("Paweł Przewięźlikowski Prezes Zarządu Selvita S.A.") summarizing the company's activities and financial performance for the year 2018 ("podsumowane działalności Grupy Kapitałowej Selvita w 2018 roku"). It discusses R&D progress (SEL24, SEL120), financing activities (share issuance in Feb 2018), growth in the service sector, personnel changes, and future outlook. This content structure—a comprehensive review of the past fiscal year's operations, strategy, and results, presented by management to shareholders—is characteristic of an Annual Report or a component thereof, often preceding or accompanying the formal 10-K filing. Given the context of a detailed operational and financial review for a full year, it strongly aligns with the scope of an Annual Report (10-K). Although it is presented as a letter/summary, the depth of the review covering the entire year suggests it is the core narrative of the annual reporting cycle, rather than just an Earnings Release (ER) or a short Fund Factsheet (FS). Since it is a detailed summary of the full year's activities, 10-K is the most appropriate classification for the underlying report type being summarized, even if this specific text is the Chairman's/CEO's letter within that report.
2019-03-28 Polish
Oświadczenie Rady Nadzorczej dotyczące sprawozdania z działalności i sprawozdania finansowego za 2018
Management Reports Classification · 99% confidence The document is titled "Ocena Rady Nadzorczej dotycząca sprawozdań Zarządu z działalności Selvita S.A. i Grupy Kapitałowej Selvita za rok 2018 oraz Sprawozdań finansowych Selvita S.A. i Grupy Kapitałowej Selvita za rok 2018" (Supervisory Board Assessment regarding the Management Board's reports on the activities of Selvita S.A. and the Selvita Capital Group for 2018 and the Financial Statements of Selvita S.A. and the Selvita Capital Group for 2018). It explicitly details the review and assessment of the Management Board's activity reports and the Financial Statements (Balance Sheet, Income Statement, Cash Flow Statement) for the full year 2018. This content strongly aligns with the scope of a comprehensive Annual Report (10-K) or a related Audit/Review document. Since it is an assessment *of* the annual financial statements and activity reports, and it contains detailed financial figures for the full year (ending Dec 31, 2018), it is closely related to the Annual Report cycle. However, the document itself is the Supervisory Board's *assessment* of these reports, not the full financial statements or the management's report itself. In the provided definitions, '10-K' is for the official yearly report, and 'AR' is for standalone audit reports/applied accounting principles. Given the focus on reviewing the full year's financial statements and management reports, and the inclusion of detailed financial line items (even if summarized), this document functions as a critical component of the annual reporting package, often filed alongside or immediately following the 10-K/Annual Report. Because it is a formal review/assessment of the full year's financial and operational reports, it fits best under the umbrella of 'Audit Report / Information' (AR) as it involves the formal review and validation of the annual financial statements by the Supervisory Board, which is analogous to an audit review function in this context, rather than being the primary 10-K filing itself. The length (4638 chars) suggests it is more than a simple announcement (RPA/RNS).
2019-03-28 Polish
Sprawozdanie biegłego rewidenta z badania sprawozdania finansowego Grupy Kapitałowej Selvita za 2018
Audit Report / Information Classification · 99% confidence The document is titled "SPRAWOZDANIE NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z BADANIA" (Independent Auditor's Report on the Audit) and specifically mentions the audit of the consolidated financial statements for the year ended December 31, 2018. It contains the auditor's opinion, the basis for the opinion, and details Key Audit Matters (Kluczowe sprawy badania). This content is characteristic of a formal audit report, which aligns with the definition for 'Audit Report / Information' (AR). Although it relates to the annual period, it is the auditor's opinion, not the full Annual Report (10-K) itself, nor is it a mere announcement of the report (RPA). FY 2018
2019-03-28 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.